Michael Lund
Emergency Medicine · Enfield, CTNPI 1306815980
Payments from drug & device makers
Across 904 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Novartis$2K
- UCB, Inc.$1K
- Pfizer$1K
- Incyte Corporation$1K
- plus $6K from 28 others
What the payments were for
- Food & beverage$15,34199%
- Education$2061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 160 | $3,008 |
| Johnson & Johnson | 63 | $1,536 |
| Novartis | 103 | $1,508 |
| UCB, Inc. | 141 | $1,327 |
| Pfizer | 65 | $1,307 |
| Incyte Corporation | 41 | $1,028 |
| E.r. Squibb & Sons, L.L.C. | 55 | $881 |
| Lilly USA, LLC | 51 | $814 |
| Sun Pharmaceutical Industries Inc. | 28 | $634 |
| Sanofi | 19 | $553 |
| Arcutis Biotherapeutics, Inc. | 29 | $433 |
| Regeneron Healthcare Solutions, Inc. | 15 | $385 |
| Galderma Laboratories, L.p. | 32 | $373 |
| LEO Pharma Inc. | 21 | $362 |
| Amgen | 16 | $319 |
| Dermavant Sciences, Inc. | 22 | $221 |
| Biofrontera Inc. | 7 | $108 |
| Boehringer Ingelheim | 5 | $106 |
| Fresenius Kabi USA, LLC | 3 | $81 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $63 |
| Organon | 2 | $60 |
| Mayne Pharma Commercial LLC | 4 | $57 |
| Almirall LLC | 2 | $48 |
| Botanix SB Inc | 2 | $47 |
| Blueprint Medicines Corporation | 2 | $42 |
| EPI Health, LLC | 2 | $42 |
| Genentech USA, Inc. | 2 | $41 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| Merz North America, Inc. | 1 | $24 |
| Smith+Nephew | 1 | $21 |
| Journey Medical Corporation | 1 | $20 |
| LNHC, Inc | 1 | $18 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sotyktu$108
How this compares
$15,547 in reported general payments places this provider in the 95th percentile of 700 emergency medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 29 | $404,075 |
| Skyrizi PenRisankizumab-Rzaa | 18 | $392,167 |
| Dupixent PenDupilumab | 47 | $194,210 |
| Dupixent SyringeDupilumab | 35 | $131,890 |
| SotyktuDeucravacitinib | 17 | $110,560 |
| Enbrel SureclickEtanercept | 12 | $91,823 |
| JubliaEfinaconazole | 13 | $18,801 |
| ZoryveRoflumilast | 13 | $10,927 |
| Clobetasol Propionate | 100 | $5,473 |
| Betamethasone Dipropionate | 73 | $4,247 |
| Fluorouracil | 56 | $3,796 |
| Tacrolimus | 34 | $3,621 |
| Metronidazole | 40 | $2,371 |
| Ketoconazole | 159 | $2,078 |
| Triamcinolone Acetonide | 173 | $2,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sotyktu | $881 | $110,56017 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $63 | $18,80113 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $433 | $10,92713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 700 emergency medicine providers in Connecticut.
Other emergency medicine in Enfield
- Lorraine HartnettEnfield$485
- Christopher MooreNew Haven$1.1M
- Michael BlochNew Haven$770K
- Basmah SafdarNew Haven$569K
- Arjun VenkateshNew Haven$92K
- Chi Kong PoonHartford$65K
- Thomas RobeyNew Haven$50K
- Kristine DoyleMiddletown$44K
- Cristiana BaloescuNew Haven$43K
- Brian BaxtPutnam$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.